| Characteristic | Increase of stock price on the day of deal announcement |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
February 2020
More information
Region
United States
Survey time period
2010 to 2019
Supplementary notes
* Completed and announced (2019) trade sales of public U.S. biopharma companies with total deal value of at least $100 million. Non-weighted average premiums.
Premium means an increase of stock price on the day of deal announcement. Only deals with an upfront consideration of at least $100 million are included in this analysis. Given the high degree of variation in premiums paid, the average numbers should be interpreted with caution.
Citation formats
